Related Experiment Video
Updated: Nov 29, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p
Wei-Song Wang1, Can-Song Zhao2
1Department of General Surgery, Zhuji Central Hospital, Zhuji, China.
Abstract:
Formononetin exhibits anti-neoplastic activities in specific types of cancers, such as colon carcinoma and breast cancer. Nevertheless, its role in suppressing gastric carcinoma (GC) growth and metastatic-associated phenotypes has not been fully understood. Here, we demonstrated that formononetin decreased the viability of GC cell line SGC-7901 and MGC-803. Furthermore, formononetin suppressed the migration and invasion abilities of GC cells. Consistent with the results in vitro, the anticancer effect of formononetin was verified using xenograft model. The expression of microRNA-542-5p (miR-542-5p), acted as an oncogene in many cancers, was identified to be upregulated in GC. Importantly, miR-542-5p might involve in formononetin exhibits anticancer activity in GC cells. Taken together, these results indicate that formononetin inhibits the growth and aggressiveness of GC cells in vitro and in vivo.
Insights
Formononetin effectively inhibits gastric carcinoma (GC) growth and spread by reducing cell viability and migration. This natural compound also downregulates the oncogene microRNA-542-5p (miR-542-5p), offering a potential therapeutic strategy for GC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Formononetin is known for anti-neoplastic effects in colon and breast cancers.
- The role of formononetin in gastric carcinoma (GC) remains largely unexplored.
- Gastric carcinoma exhibits aggressive growth and metastatic potential.
Purpose of the Study:
- To investigate the anticancer effects of formononetin on gastric carcinoma cells.
- To elucidate the underlying molecular mechanisms, including the role of microRNA-542-5p (miR-542-5p).
- To evaluate formononetin's efficacy in preclinical models of GC.
Main Methods:
- Cell viability assays on GC cell lines (SGC-7901, MGC-803).
- Migration and invasion assays for GC cells treated with formononetin.
- In vivo studies using a xenograft model to assess anticancer effects.
- Analysis of microRNA-542-5p (miR-542-5p) expression in GC.
Main Results:
- Formononetin significantly reduced the viability of SGC-7901 and MGC-803 GC cell lines.
- Formononetin suppressed the migration and invasion capabilities of GC cells in vitro.
- Anticancer effects were confirmed in a xenograft model.
- Upregulation of microRNA-542-5p (miR-542-5p) was observed in GC, and it may mediate formononetin's activity.
Conclusions:
- Formononetin demonstrates potent inhibitory effects on gastric carcinoma cell growth and aggressiveness.
- The compound's action involves the modulation of microRNA-542-5p (miR-542-5p).
- Formononetin presents a promising therapeutic candidate for gastric carcinoma treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Drugs that Stabilize Microtubules
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Drugs that Destabilize Microtubules

